# US Molecular Diagnostics Transplant Market

> US Molecular Diagnostics for Transplant Market Research Report By Product (Reagents & Kits, Instruments, Services & Software), By Technology (Polymerase Chain Reaction (PCR), Sequencing, Microarray, Others) and By End User (Hospitals and Transplant Centers, Research Laboratories & Academic Institutes, Others) -Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.08%
- **2024:** $ 206.34 Million
- **2025:** $ 224.71 Million
- **2035:** $ 485.1 Million
- **Key Players:** Thermo Fisher Scientific (US), Abbott Laboratories (US), Roche Diagnostics (US), Qiagen (US), Hologic (US), Illumina (US), Becton Dickinson (US), Genomic Health (US), Myriad Genetics (US)

**Report ID:** MRFR/MED/51800-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-molecular-diagnostics-transplant-market-53561

---

## Market Summary

## **US Molecular Diagnostics for Transplant Market Overview**

As per MRFR analysis, the US Molecular Diagnostics for Transplant Market Size was estimated at 189.45 (USD Million) in 2023. The US Molecular Diagnostics for Transplant Market Industry is expected to grow from 200(USD Million) in 2024 to 510 (USD Million) by 2035. The US Molecular Diagnostics for Transplant Market CAGR (growth rate) is expected to be around 8.883% during the forecast period (2025 - 2035).

**Key US Molecular Diagnostics for Transplant Market Trends Highlighted**

The US Molecular Diagnostics for Transplant market is experiencing substantial growth as a result of the growing demand for personalized medicine, advancements in technology, and the necessity for enhanced patient outcomes. The United States reports thousands of organ transplant procedures annually, which has prompted healthcare providers to pursue more effective diagnostic solutions. One of the primary market drivers is the increasing prevalence of organ transplants. The early detection of infectious diseases and organ rejection is becoming increasingly important for transplant patients as a result of technological advancements in molecular testing.

Additionally, there are a plethora of opportunities to investigate in the domain of regulatory policies that promote innovation in diagnostic instruments. The US Food and Drug Administration (FDA) is currently engaged in the active pursuit of expediting the approval process for molecular diagnostics, in an effort to increase the availability of new tests in the market. Furthermore, there is an increasing trend of collaboration between diagnostic firms and hospitals, which enables the creation of customized solutions that are specifically designed to meet the requirements of individual patients.

Recent trends suggest that there is an increasing emphasis on non-invasive testing methods, such as liquid biopsies, which are less taxing on patients and offer real-time insights into organ function. The integration of artificial intelligence and big data in molecular diagnostics is also on the rise, allowing healthcare providers to analyze vast quantities of data to improve decision-making.

The US Molecular Diagnostics for Transplant market is poised for ongoing growth and evolution, in accordance with the broader trend toward more precise and personalized healthcare solutions, thanks to the support of government initiatives that are designed to enhance patient care and transplant success rates.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

**US Molecular Diagnostics for Transplant Market Drivers**

**Increasing Prevalence of Organ Transplant Procedures**

The US has seen a substantial rise in organ transplant procedures over the past decade, which significantly drives the US Molecular Diagnostics for Transplant Market Industry. According to the United Network for Organ Sharing, the number of organ transplants performed in the US grew from 28,000 in 2008 to over 39,000 in 2020. This 39% increase reflects not only advancements in surgical techniques but also improvements in diagnostic technologies that help ensure the compatibility and success of transplants. Established organizations like the American Society of Transplantation play a crucial role in promoting awareness and facilitating research to improve transplant outcomes.

With molecular diagnostics providing essential insights into patient-specific treatment protocols, the demand for these technologies is expected to surge in conjunction with the rising rates of organ transplantation.

**Advancements in Molecular Diagnostic Technologies**

Rapid advancements in molecular diagnostic technologies are driving growth in the US Molecular Diagnostics for Transplant Market Industry. The introduction of next-generation sequencing (NGS) and polymerase chain reaction (PCR) techniques has improved the detection of donor-specific antibodies and pathogen levels significantly. The Centers for Disease Control and Prevention reports that these technologies enhance the precision of diagnosing transplant-related complications.
Companies such as Genentech have invested heavily in developing innovations that improve the applications of molecular diagnostics for transplant patients, thus enhancing patient outcomes and driving market growth.

**Growing Awareness and Acceptance of Personalized Medicine**

The trend towards personalized medicine is reshaping treatment paradigms, subsequently boosting the US Molecular Diagnostics for Transplant Market Industry. With the growing wealth of genomic data and the need for individualized care, there is a heightened focus on tailoring treatment based on individual patient profiles. The National Institutes of Health has noted that personalized medicine can significantly improve transplant outcomes, motivating both patients and healthcare providers to adopt these approaches.
As more transplant centers advocate for the use of molecular diagnostics to provide tailored treatment options, the market is expected to experience accelerated growth.

**US Molecular Diagnostics for Transplant Market Segment Insights**

**Molecular Diagnostics for Transplant Market Product Insights**

The US Molecular Diagnostics for Transplant Market, centered around the Product segment, presents a diverse landscape with critical components that drive the sector. This segment plays a pivotal role in enabling accurate and timely diagnoses required for transplant procedures. Among these components, Reagents and Kits serve as the backbone, facilitating the essential reactions necessary for molecular testing. Their importance is underscored by the growing reliance on personalized medicine, where targeted treatments are developed based on individual molecular profiles. Instruments, on the other hand, represent the technological forefront of molecular diagnostics, with advanced machinery that enhances testing accuracy and efficiency.

This capability is essential in transplantation, where precision can significantly impact outcomes. Services and Software also contribute to this segment, offering crucial analytical tools and support systems that streamline workflows and ensure quality control, thereby enhancing the overall efficiency and reliability of diagnostic services in transplants. The increasing demand for organ transplants in the US creates ample opportunities for growth within this segment, driven by continuous innovations and advancements in technology.

Moreover, as healthcare moves towards more integrated approaches, the collaboration between these componentsReagents and Kits, Instruments, and Services, and Softwarebecomes vital in addressing the complex needs of patients and healthcare providers alike, ultimately improving patient care in the transplantation process. As a result, the Product segment is expected to see sustained interest and investment, reflecting the essential need for accurate and reliable diagnostic capabilities in the transplant domain.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

**Molecular Diagnostics for Transplant Market Technology Insights**

The Technology segment of the US Molecular Diagnostics for Transplant Market encompasses various advanced methodologies that play a crucial role in transplant diagnostics. Polymerase Chain Reaction (PCR) stands prominent in this segment, as it allows for the amplification of specific DNA sequences, enabling rapid and accurate detection of pathogens and genetic disorders that could affect transplant success. Sequencing technologies have revolutionized the field by providing comprehensive insights into genetic variations, thus facilitating personalized medicine approaches in transplant settings. Microarrays also contribute by allowing simultaneous analysis of multiple genetic markers, which aids in donor-recipient matching and monitoring post-transplant complications.

In addition to these, other innovative technologies in this segment enhance diagnostic capabilities, thereby improving patient outcomes and driving market growth. The continuous advancements in technology, alongside the increasing demand for precise diagnostic tools in transplants, are pivotal for shaping the landscape of the US Molecular Diagnostics for Transplant Market. The heightened focus on precision medicine and personalized healthcare solutions further amplifies the importance of these technologies, ensuring their relevance in contemporary clinical practices.

**Molecular Diagnostics for Transplant Market End User Insights**

The US Molecular Diagnostics for Transplant Market is significantly shaped by its end-user landscape, which is composed of Hospitals and Transplant Centers, Research Laboratories, and Academic Institutes, as well as other entities involved in healthcare. Hospitals and Transplant Centers play a crucial role as they are often the primary facilities for conducting molecular diagnostic tests related to transplantation, ensuring accurate patient assessments and enhancing transplant outcomes.

Research Laboratories and Academic Institutes contribute to this market by driving innovations through extensive Research and Development efforts, focusing on improving diagnostic methods and understanding transplant compatibility, which are vital for patient safety and efficacy in transplants. Other users, including private laboratories and specialty clinics, also leverage molecular diagnostics to cater to specific patient needs, further expanding the market’s reach. The dynamic interplay among these end users highlights a collaborative approach to improving patient care, while also emphasizing the ongoing need for effective molecular diagnostic solutions in the context of transplantation.

The increasing focus on precision medicine within the US healthcare system aligns well with these segments, fueling ongoing growth and advancements in this important sector.

**US Molecular Diagnostics for Transplant Market Key Players and Competitive Insights**

The US Molecular Diagnostics for Transplant Market is characterized by rapid technological advancements and intense competition among various players aiming to enhance patient outcomes through improved diagnostic precision and monitoring capabilities. The market focuses on the development of sophisticated tools and assays that enable healthcare providers to evaluate transplant compatibility, monitor transplant rejection, and ensure long-term success post-transplantation. As these technologies evolve, companies are increasingly engaged in strategic collaborations, product innovations, and expansions to solidify their market presence.

The regulatory landscape, driven by the need for safety and efficacy in transplant diagnostics, further influences competitive dynamics, necessitating compliance and quality assurance measures from market participants. Furthermore, the rising emphasis on personalized medicine in transplant care is expected to shape the market's growth trajectory, as stakeholders seek to leverage molecular diagnostics to tailor treatments to individual patient profiles. CareDx has established itself as a leading entity in the US Molecular Diagnostics for Transplant Market, primarily focusing on delivering innovative solutions that improve transplant outcomes.

The company’s strength lies in its pioneering approach to developing non-invasive testing technologies, particularly in the realm of transplant monitoring. CareDx's signature products, primarily aimed at organ transplant patients, utilize molecular assays to provide real-time insights into organ health, enabling healthcare providers to detect rejection episodes early. This positions CareDx strongly within the market, as it addresses critical needs in post-transplant care. Furthermore, the company maintains strategic partnerships with healthcare providers and research institutions to enhance the adoption of its diagnostic tools, ensuring its prominence in the competitive landscape of transplant diagnostics.

Through continuous research and innovation, CareDx is well-placed to meet the growing demands for efficient and effective transplant monitoring solutions. Abbott Laboratories is another significant player in the US Molecular Diagnostics for Transplant Market, known for its comprehensive portfolio of diagnostic products and services tailored to enhance transplant care. Abbott Laboratories offers advanced molecular diagnostics that include assays capable of assessing donor-recipient compatibility and monitoring graft health, thereby facilitating timely interventions when necessary. The company has a solid market presence strengthened by its robust distribution network and established relationships with healthcare systems across the US.

Abbott's strengths are augmented by its commitment to innovation, underscored by substantial investments in research and development aimed at expanding its diagnostic offerings. Additionally, Abbott Laboratories engages in strategic mergers and acquisitions to bolster its capabilities and market reach, reflecting its proactive approach to capturing growing opportunities in the transplant diagnostic arena. Through its continued focus on quality and innovation, Abbott reinforces its position within this competitive market segment.

**Key Companies in the US Molecular Diagnostics for Transplant Market Include**

**US Molecular Diagnostics for Transplant Market Industry Developments**

The US Molecular Diagnostics for Transplant Market has been witnessing notable developments recently. In September 2023, CareDx launched a new AlloSure Kidney test aimed at enhancing the monitoring of kidney transplant patients, addressing the urgent need for accurate post-transplant assessments. Similarly, Natera announced advancements in its donor-derived cell-free DNA testing, focusing on improving organ transplant outcomes. Furthermore, Abbott Laboratories has expanded its diagnostic portfolio to include cutting-edge molecular technologies, which significantly enhance transplant success rates.

The market has also seen growth in valuation due to increasing demand for rapid and accurate diagnostics, with estimates suggesting a significant shift in market dynamics over the past three years, primarily driven by the rise in organ transplant procedures in the US. Notably, no recent merger or acquisition activity was specifically reported among the key companies, such as Roche Diagnostics and Thermo Fisher Scientific, within the last few months. However, companies continue exploring strategic partnerships to broaden their diagnostic capabilities.

As the market evolves, these technological advancements and partnerships are expected to further enhance patient outcomes and operational efficiencies in transplant medicine.

**Molecular Diagnostics For Transplant Market Segmentation Insights**

## Market Drivers

### Focus on Personalized Medicine

The shift towards personalized medicine is a significant driver in the US Molecular Diagnostics For Transplant Market. Personalized medicine tailors treatment plans based on individual genetic profiles, which is particularly relevant in transplant scenarios where compatibility is crucial. Molecular diagnostics enable healthcare providers to assess the genetic makeup of both donors and recipients, thereby optimizing transplant outcomes. This trend is supported by an increasing body of research demonstrating that personalized approaches can reduce the risk of rejection and improve long-term success rates. As healthcare systems in the US continue to embrace personalized medicine, the demand for molecular diagnostic tools is expected to rise. This shift not only enhances patient care but also aligns with broader healthcare goals of improving efficiency and reducing costs associated with transplant procedures.

### Increased Awareness and Education

Increased awareness and education regarding the importance of molecular diagnostics in transplantation is a key driver for the US Molecular Diagnostics For Transplant Market. Healthcare professionals are becoming more knowledgeable about the benefits of molecular testing, leading to greater adoption in clinical practice. Educational initiatives and training programs are being implemented to inform clinicians about the latest advancements in molecular diagnostics and their applications in transplant medicine. This heightened awareness is fostering a culture of evidence-based practice, where decisions are increasingly guided by molecular data. As healthcare providers recognize the value of these diagnostics in improving transplant outcomes, the demand for molecular diagnostic tests is expected to grow. This trend is likely to enhance the overall quality of care in transplant programs across the United States.

### Rising Incidence of Chronic Diseases

The US Molecular Diagnostics For Transplant Market is also influenced by the rising incidence of chronic diseases, which often lead to organ failure and the need for transplants. Conditions such as diabetes, hypertension, and liver disease are becoming increasingly prevalent in the US population, necessitating more organ transplants. According to the Organ Procurement and Transplantation Network (OPTN), the number of transplants performed annually has been steadily increasing, highlighting the growing demand for effective diagnostic tools. Molecular diagnostics play a critical role in ensuring the success of these transplants by providing essential information about donor-recipient compatibility. As the prevalence of chronic diseases continues to rise, the market for molecular diagnostics in transplant settings is likely to expand, driven by the need for improved patient management and outcomes.

### Regulatory Support and Reimbursement Policies

The US Molecular Diagnostics For Transplant Market benefits from robust regulatory support and favorable reimbursement policies. The Food and Drug Administration (FDA) has established clear guidelines for the approval of molecular diagnostic tests, which facilitates quicker market entry for innovative products. Additionally, the Centers for Medicare & Medicaid Services (CMS) has recognized the importance of molecular diagnostics in transplant procedures, leading to improved reimbursement rates for these tests. This regulatory environment encourages investment in research and development, as companies are more likely to pursue new diagnostic solutions knowing that they will receive support from regulatory bodies. The combination of regulatory clarity and financial incentives is likely to drive market growth, as healthcare providers increasingly adopt molecular diagnostics to enhance patient care in transplant settings.

### Technological Advancements in Molecular Diagnostics

The US Molecular Diagnostics For Transplant Market is experiencing rapid growth due to technological advancements in diagnostic tools. Innovations such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) techniques have enhanced the accuracy and speed of transplant compatibility testing. These technologies allow for the identification of genetic markers that predict transplant rejection, thereby improving patient outcomes. The market is projected to grow at a compound annual growth rate (CAGR) of approximately 10% over the next five years, driven by the increasing adoption of these advanced diagnostic methods. Furthermore, the integration of artificial intelligence in data analysis is expected to streamline the diagnostic process, making it more efficient and reliable. As a result, healthcare providers are increasingly investing in these technologies to enhance their transplant programs.

## Future Outlook

The US [Molecular Diagnostics For Transplant Market](https://www.marketresearchfuture.com/reports/molecular-diagnostics-for-transplant-market-11826) is projected to grow at an 8.08% CAGR from 2025 to 2035, driven by technological advancements, increasing transplant procedures, and rising demand for personalized medicine.

**New opportunities:**

- Development of portable molecular diagnostic devices for point-of-care testing. Integration of AI algorithms for predictive analytics in transplant compatibility. Expansion of telehealth services for remote patient monitoring and diagnostics.

By 2035, the market is expected to be robust, driven by innovation and increased adoption of molecular diagnostics.

## Segment Insights

### By Application: Transplant Rejection Monitoring (Largest) vs. Infectious Disease Testing (Fastest-Growing)

In the US Molecular Diagnostics For Transplant Market, Transplant Rejection Monitoring currently holds the largest market share among application segments, as it is essential for managing and anticipating organ rejection risks in transplant patients. Infectious Disease Testing, however, is rapidly gaining traction due to the increasing incidence of infections in transplant patients and the growing awareness of the importance of monitoring these conditions post-transplant. As the healthcare landscape evolves, these two applications are shaping the future priorities of healthcare providers in this sector.

Transplant Rejection Monitoring: Dominant vs. Post-Transplant Monitoring: Emerging

Transplant Rejection Monitoring remains the dominant application in the US market, driven by its critical role in the survival of transplant recipients. This segment benefits from advanced diagnostic technologies that enable timely detection of organ rejection, thus improving patient outcomes. On the other hand, Post-Transplant Monitoring, while emerging, is witnessing increased investment and interest due to the necessity of long-term patient management strategies. This segment focuses on ongoing assessments of transplant patients to manage potential complications, and its growth is largely fueled by the rising success rates of transplants and the increasing emphasis on personalized medicine.

### By Technology: Polymerase Chain Reaction (Largest) vs. Next Generation Sequencing (Fastest-Growing)

In the US Molecular Diagnostics For Transplant Market, the technology segment showcases a diverse range of methodologies with Polymerase Chain Reaction (PCR) leading the market due to its established applications and reliability in detecting and quantifying nucleic acids. Following PCR, Next Generation Sequencing (NGS) is rapidly gaining traction, becoming a significant player in transplant diagnostics, particularly for its ability to analyze multiple genes simultaneously, thereby enhancing the scope of genetic profiling.

Technology: PCR (Dominant) vs. NGS (Emerging)

PCR remains the dominant technology in the molecular diagnostics market for transplants, credited for its accuracy and speed in amplifying specific DNA sequences. NGS, however, emerges as a groundbreaking approach, enabling comprehensive genomic analysis that accommodates more complex scenarios in transplant diagnostics. The flexibility and high throughput of NGS are propelling its adoption, making it suitable for personalized medicine applications. Both technologies have distinct operational benefits, with PCR being cost-effective for routine tests and NGS offering depth in genetic insights, which is critical for understanding transplant compatibility and potential rejection.

### By End Use: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the US Molecular Diagnostics for Transplant Market, hospitals hold the largest market share among the end use segments. Their extensive facilities and access to advanced diagnostic technologies enable them to conduct a wide range of molecular tests, catering to the growing needs of transplant patients. On the other hand, diagnostic laboratories are also significant players, but their share is steadily increasing as the demand for rapid and accurate testing rises, particularly in support of transplantation efforts.

End Use: Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging)

Hospitals constitute the dominant segment in the US Molecular Diagnostics for Transplant Market due to their capacity to deliver comprehensive patient care and a range of diagnostic services. They leverage state-of-the-art technologies and skilled personnel to provide timely testing for transplant compatibility and monitoring. Conversely, diagnostic laboratories emerge as a crucial segment, rapidly adapting to the market’s evolving demands. Their growth is fueled by advancements in molecular technology and an increase in outsourcing testing from hospitals, underscoring their role in enhancing the efficiency and accuracy of transplant diagnostics.

### By Sample Type: Blood (Largest) vs. Urine (Fastest-Growing)

In the US Molecular Diagnostics For Transplant Market, the Blood sample type holds the largest market share, reflecting its critical role in diagnostic procedures. This dominance can be attributed to the established prevalence of blood tests in various transplant-related diagnostics, where they provide essential insights into the patient's immunological status and organ compatibility. The utilization of blood samples is further bolstered by advancements in testing technologies, ensuring accuracy and reliability in results. Conversely, Urine samples are emerging as the fastest-growing segment in this market. This growth is driven by an increasing awareness of the non-invasive nature of urine tests, which appeals to both healthcare providers and patients. Moreover, advancements in urine-based molecular diagnostic techniques are broadening their application scope, making them viable alternatives to traditional blood tests for certain transplant evaluations.

Blood (Dominant) vs. Tissue (Emerging)

In the realm of the US Molecular Diagnostics For Transplant Market, Blood remains the dominant sample type due to its extensive application in testing and monitoring transplant patients. It offers a wealth of information, making it indispensable for diagnostics. In contrast, Tissue samples are gaining traction as an emerging alternative. Their usage is growing with the rise in personalized medicine, allowing for specific cellular level assessments relevant to organ transplants. Tissue sampling provides insights into the genetic and histological aspects of transplantation, enabling tailored treatment plans. This complementarity between Blood and Tissue sample types highlights an evolving landscape, where both can coexist and cater to distinct diagnostic needs.

### By Test Type: Molecular Testing (Largest) vs. Genetic Testing (Fastest-Growing)

In the US Molecular Diagnostics For Transplant Market, the market share distribution among test types displays a clear hierarchy. Molecular Testing holds the largest share, primarily due to its precision, sensitivity, and rapid results, which are essential for transplant evaluation processes. Conversely, Genetic Testing, while currently smaller in market share, is rapidly gaining traction, driven by advancements in genomic research and increasing demand for personalized medicine.

Testing Type: Molecular Testing (Dominant) vs. Genetic Testing (Emerging)

Molecular Testing is characterized by its advanced techniques that allow for the detection of genetic material from pathogens and immune responses, making it crucial for transplant compatibility assessments. Its dominance in the market stems from its ability to provide quick and accurate results, which are instrumental in improving patient outcomes. On the other hand, Genetic Testing is emerging as an essential segment, fueled by innovations in genomics and a growing emphasis on personalized treatment plans. Genetic Testing offers insights into a patient’s genetic predisposition for transplant rejection and response, thus playing a critical role in enhancing post-transplant care.

## Competitive Benchmarking

The Molecular Diagnostics For Transplant Market is characterized by a dynamic competitive landscape, driven by advancements in technology and increasing demand for personalized medicine. Key players such as Thermo Fisher Scientific (US), Abbott Laboratories (US), and Roche Diagnostics (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. These companies focus on developing cutting-edge diagnostic solutions that improve transplant outcomes, thereby shaping the competitive environment through their commitment to research and development, as well as their ability to respond to evolving healthcare needs.
In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Illumina (US) and Hologic (US) suggests a trend towards consolidation, as these firms seek to expand their product offerings and geographic reach.
In December 2025, Thermo Fisher Scientific (US) announced the launch of a new molecular diagnostic platform specifically designed for transplant patients, which integrates advanced genomic sequencing technologies. This strategic move is likely to enhance the company's portfolio and position it as a leader in precision medicine, catering to the growing demand for tailored transplant solutions. The introduction of this platform may also facilitate better patient outcomes through more accurate diagnostics.
In November 2025, Abbott Laboratories (US) expanded its collaboration with a leading transplant center to develop a comprehensive suite of diagnostic tests aimed at improving organ transplant success rates. This partnership underscores Abbott's commitment to innovation and its strategic focus on enhancing patient care through advanced diagnostics. By aligning with key healthcare institutions, Abbott is likely to strengthen its market presence and drive adoption of its diagnostic solutions.
In October 2025, Roche Diagnostics (US) acquired a biotechnology firm specializing in next-generation sequencing technologies. This acquisition is expected to bolster Roche's capabilities in molecular diagnostics, particularly in the transplant sector. By integrating these advanced technologies, Roche may enhance its product offerings and improve its competitive edge in a rapidly evolving market.
As of January 2026, current trends in the Molecular Diagnostics For Transplant Market indicate a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances among key players are shaping the landscape, fostering innovation and collaboration. The competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, reliability in supply chains, and the development of innovative solutions that address the specific needs of transplant patients.

## Recent News & Developments

The US Molecular Diagnostics for Transplant Market has been witnessing notable developments recently. In September 2023, CareDx launched a new AlloSure Kidney test aimed at enhancing the monitoring of kidney transplant patients, addressing the urgent need for accurate post-transplant assessments. Similarly, Natera announced advancements in its donor-derived cell-free DNA testing, focusing on improving organ transplant outcomes. Furthermore, Abbott Laboratories has expanded its diagnostic portfolio to include cutting-edge molecular technologies, which significantly enhance transplant success rates.

The market has also seen growth in valuation due to increasing demand for rapid and accurate diagnostics, with estimates suggesting a significant shift in market dynamics over the past three years, primarily driven by the rise in organ transplant procedures in the US. Notably, no recent merger or acquisition activity was specifically reported among the key companies, such as Roche Diagnostics and Thermo Fisher Scientific, within the last few months. However, companies continue exploring strategic partnerships to broaden their diagnostic capabilities.

As the market evolves, these technological advancements and partnerships are expected to further enhance patient outcomes and operational efficiencies in transplant medicine.

## Report Scope

| MARKET SIZE 2024 | 206.34(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 224.71(USD Million) |
| MARKET SIZE 2035 | 485.1(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.08% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Thermo Fisher Scientific (US), Abbott Laboratories (US), Roche Diagnostics (US), Qiagen (US), Hologic (US), Illumina (US), Becton Dickinson (US), Genomic Health (US), Myriad Genetics (US) |
| Segments Covered | Application, Technology, End Use, Sample Type, Test Type |
| Key Market Opportunities | Advancements in personalized medicine enhance diagnostic accuracy in the US Molecular Diagnostics For Transplant Market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive growth in the US Molecular Diagnostics For Transplant Market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US Molecular Diagnostics For Transplant Market?**
A: The market valuation was 206.34 USD Million in 2024.

**Q: What is the projected market size for the US Molecular Diagnostics For Transplant Market by 2035?**
A: The projected valuation for 2035 is 485.1 USD Million.

**Q: What is the expected CAGR for the US Molecular Diagnostics For Transplant Market during the forecast period 2025 - 2035?**
A: The expected CAGR is 8.08% during the forecast period 2025 - 2035.

**Q: Which companies are considered key players in the US Molecular Diagnostics For Transplant Market?**
A: Key players include Thermo Fisher Scientific, Abbott Laboratories, Roche Diagnostics, Qiagen, Hologic, Illumina, Becton Dickinson, Genomic Health, and Myriad Genetics.

**Q: What segment had the highest valuation in the US Molecular Diagnostics For Transplant Market in 2024?**
A: The Donor-Recipient Matching segment had a valuation of 60.0 to 150.0 USD Million.

**Q: How does the Infectious Disease Testing segment perform in terms of market valuation?**
A: The Infectious Disease Testing segment ranged from 50.0 to 120.0 USD Million.

**Q: What is the market valuation for the Next Generation Sequencing technology segment?**
A: The Next Generation Sequencing segment had a valuation between 70.0 and 180.0 USD Million.

**Q: Which end-use segment is projected to have the highest market valuation?**
A: The Hospitals segment is projected to range from 82.54 to 195.0 USD Million.

**Q: What is the valuation range for the Molecular Testing type in the US Molecular Diagnostics For Transplant Market?**
A: The Molecular Testing type ranged from 70.07 to 165.0 USD Million.

**Q: What sample type is expected to show significant market performance in the future?**
A: The Blood sample type is projected to range from 60.0 to 140.0 USD Million.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-molecular-diagnostics-transplant-market-53561*